Overview
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer.
(Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Eligibility
Inclusion Criteria:
- Triple negative breast cancer
- Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not
- Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy
- Sign to informed consent
Exclusion Criteria:
- Patients with difficulty in obtaining sufficient samples